Yahoo
Brussels - Delayed Quote EUR

Biotalys NV (BTLS.BR)

2.0750 +0.0770 (+3.86%)
As of 10:04:53 AM GMT+1. Market Open.
Chart Range Bar
Loading chart for BTLS.BR
  • Previous Close 1.9980
  • Open 2.0000
  • Bid --
  • Ask --
  • Day's Range 1.9860 - 2.0950
  • 52 Week Range 1.5600 - 4.9500
  • Volume 18,136
  • Avg. Volume 20,193
  • Market Cap (intraday) 94.307M
  • Beta (5Y Monthly) 1.49
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4300
  • Earnings Date Aug 20, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 4.70
  • Moby Rating Neutral

Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and other fungi in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; BIOFUN-4 targeting oomycetes in fruits and vegetables; BIOFUN-8 targeting altenaria in fruits, vegetables, and specialty crops; and BioIns-2 targeting key insect pests. The company was formerly known as Agrosavfe NV and changed its name to Biotalys NV in December 2019. Biotalys NV was incorporated in 2013 and is headquartered in Ghent, Belgium.

biotalys.com

37

Full Time Employees

December 31

Fiscal Year Ends

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .

YTD Return

BTLS.BR
38.24%
BEL 20 (^BFX)
19.04%

1-Year Return

BTLS.BR
57.39%
BEL 20 (^BFX)
22.99%

3-Year Return

BTLS.BR
34.34%
BEL 20 (^BFX)
74.87%

5-Year Return

BTLS.BR
71.02%
BEL 20 (^BFX)
37.88%

Analyst Insights

View More

Analyst Price Targets

3.40
4.70 Average
2.0750 Current
6.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -36.14%

  • Return on Equity (ttm)

    -96.43%

  • Revenue (ttm)

    266k

  • Net Income Avi to Common (ttm)

    -16.77M

  • Diluted EPS (ttm)

    -0.4300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    14.04M

  • Total Debt/Equity (mrq)

    21.63%

  • Levered Free Cash Flow (ttm)

    -7.57M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: